COST Action CA21111

One Health drugs against parasitic vector borne diseases in Europe and

beyond (OneHealthdrugs)

Our Mission

OneHealthdrugs aims to coordinate the discovery of drugs that stop vector-borne infections in both human and veterinary settings according to

the principles of the optimal profile for both organisms, increasing

quality and reducing environmental impact.

What we do

Want to know more?

OneHealthdrugs aims at coordinating the discovery of drugs halting H&A VBD $\ensuremath{\mathsf{NBD}}$

keeping with the principles of optimal profile for both organisms, increasing the quality and delivery technologies. The COST Action is the

ideal platform aiming at the integration and generation of synergies among

drug R&D experts from the chemical / biological / human / veterinary and

earth science within academies, SMEs, industries, governments. The platform encompasses pre-clinical drug discovery, animal studies, and drug

delivery. Strategies such as bioinformatics, PROTAC, nanotechnology will

be enhanced.

OneHealthdrugs will impact in Europe and in disease-endemic countries. The

Action will provide a compounds database and a white chart about the $% \left({{{\boldsymbol{x}}_{i}}} \right)$

discovery of new drugs for $\ensuremath{\mathtt{H\&A}}$ infections. Expected benefits include the

transfer of academia-industry and Northern-Southern world knowledge.

Conferences, training schools for advanced technologies, and STSMs are

planned. Novel communication technologies to disseminate the Action results to a broad audience including scientists, stakeholders, and citizens are planned. Young researchers will be trained on advanced techniques.